We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02570932
Recruitment Status : Completed
First Posted : October 7, 2015
Last Update Posted : April 5, 2018
Sponsor:
Information provided by (Responsible Party):
Jesús Vaquero Crespo, M.D., Puerta de Hierro University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to analyze the potential clinical efficacy of intrathecal administration, in the subarachnoid space, of in vitro expanded autologous adult bone marrow mesenchymal stem cells in the treatment of patients with established chronic spinal cord injury (LEM).

Condition or disease Intervention/treatment Phase
Spinal Cord Injury Biological: Autologous Mesenchymal Bone Marrow Cell Phase 2

Detailed Description:

This is a clinical trial phase II, single-center, non-randomized, uncontrolled, open prospective follow-up of a cohort of patients with chronic spinal cord injury.

Patients are treated with repeated administrations of in vitro expanded autologous adult bone marrow mesenchymal stem cells.

The expanded cells are administered in the subarachnoid space by lumbar puncture. The minimum duration of the follow-up period for each patient is 10 months after the first administration.

The study duration is 24 months, that include recruiting, treatment and follow period for all patients. For each patient at the first day will be administered the first cellular doses, then 3 doses will be administrated every 3 months. At the end of the clinical trial, a completed check of all obtained parameters will be performed.

It is considered Day 1 for each patient the first day of the first cell administration. The remaining 2 doses will be administered at intervals of 3 months from the first administration (of the treatment period after, months 4 and 7). At the end of the study will be performed a full assessment of the variables collected along the study trial.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intrathecal Administration (Pattern 100/3) of Expanded Autologous Adult Bone Marrow Mesenchymal Stem Cells in Established Chronic Spinal Cord Injuries
Study Start Date : July 2015
Actual Primary Completion Date : December 4, 2017
Actual Study Completion Date : December 4, 2017

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Autologous Mesenchymal Bone Marrow Cell

All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)

Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration.

 Biological: Autologous Mesenchymal Bone Marrow Cell

Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.

Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation. [ Time Frame: from baseline until the end of the follow up period (24 months) ]

    Efficacy evaluation by measuring the change in motor and sensory functions by using the international Association of Neurorestoratology-Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS). This scale includes 9 categories with 16 items in total (plus one optional category).

    The maximum possible score is 48; the lowest possible score is 0.



Secondary Outcome Measures :
  1. Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment [ Time Frame: from baseline to 24 months ]
    The clinical evaluation of possible adverse effects is performed throughout the entire study duration and will be measured by descriptive analysis

  2. Changes in PENN score are considerate for the motor and sensory functions evaluation [ Time Frame: from baseline until the end of the follow up period (24 months) ]
    Efficacy evaluation by measuring the change in motor and sensory functions by using the Penn Spasm Frequency Scale that is Composed of 2-parts: the first is a self-report measure with items on 5-point scales developed to augment clinical ratings of spasticity and provides a more comprehensive assessment of spasticity

  3. Changes in VAS score are considerate for quantification of pain [ Time Frame: from baseline until the end of the follow up period (24 months) ]
    Efficacy evaluation by measuring the change in pain by using the visual analogue scale (VAS). The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks, depending on his feel of pain.

  4. Changes in BDS score are considerate for the Assessment of the functional status [ Time Frame: from baseline until the end of the follow up period (24 months) ]
    Efficacy evaluation by measuring the change in the Blepharospasm Disability Scale (BDS)

  5. Changes in GEFFNER score are considerate for the Assessment of the functional status [ Time Frame: from baseline until the end of the follow up period (24 months) ]
    Efficacy evaluation by measuring the change in the GEFFNER score


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Spinal cord injury (Level A, B, C or D in ASIA scales), clinically stable for at least 6 months prior to study start.
  2. Previous studies of Neurophysiology, MRI and Urology to allow useful baseline, in order that they can be compared with the same scans following treatment, and to obtain objective data of potential efficacy.
  3. Age between 18 and 70 years.
  4. Men and women of childbearing age must compromise to use contraceptives from the time at which the removal of cells from the bone marrow is performed until 6 months after the Mesenchymal Stem Cells (MSC) last administration by lumbar puncture.
  5. Possibility of follow up and ability to perform ambulatory physical therapy throughout all treatment period.
  6. Written informed consent, according to the law in force.
  7. Hematologic, creatinine, Serum glutamic oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase (SGPT) parameters, within the normal range, according to laboratory standards. However, slight modifications that are considered significant in the context of treatment to be performed, according to the criterion of the research team, are accepted.

Exclusion Criteria:

  1. Age below 18 years or above 70.
  2. Pregnancy or lactation.
  3. Current neoplastic disease or in the previous 5 years (diagnosed or treated).
  4. Patients with systemic disease that represents an added risk to treatment.
  5. Alterations in the genetic study performed to discard risk cell transformation in the expansion process.
  6. Patients with doubts about possible cooperation in the maintenance physical therapy or in the controls carried out during the study
  7. Neurodegenerative disease added.
  8. History of substance abuse, psychiatric disease or allergy to protein products used in the process of cell expansion.
  9. Positive serology for HIV and syphilis.
  10. Active Hepatitis B or Hepatitis C, according to serology analysis.
  11. If in the opinion of the researcher there is some other reason why the patient is not considered candidate for the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02570932


Locations
Layout table for location information
Spain
Hospital Puerta de Hierro
Majadahonda, Madrid, Spain, 28222
Sponsors and Collaborators
Puerta de Hierro University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Jesús JV Vaquero Crespo, MD. Hospital Universitario Puerta de Hierro-Majadahonda
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Jesús Vaquero Crespo, M.D., Principal Investigator, Puerta de Hierro University Hospital
ClinicalTrials.gov Identifier: NCT02570932    
Other Study ID Numbers: CME-LEM3
2014-005613-24 ( EudraCT Number )
First Posted: October 7, 2015    Key Record Dates
Last Update Posted: April 5, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication
Time Frame: Starting at CTD submission to authorities.
Access Criteria: Spanish competent authority.
Keywords provided by Jesús Vaquero Crespo, M.D., Puerta de Hierro University Hospital:
Adult Autologous Bone Marrow Mesenchymal Cells Expanded
chronic spinal cord injury (SCI)
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Wounds and Injuries
Spinal Cord Diseases
 Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System